Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nephros 510(k) woes

This article was originally published in The Gray Sheet

Executive Summary

Kidney dialysis product maker plans to meet with FDA to discuss next steps after the agency rejected a 510(k) pre-market submission for the firm's hemodiafiltration (HDF) system, designed to improve quality of life in end-stage renal disease (ESRD) patients. FDA sent a not-substantially-equivalent decision letter to the firm June 30, but Nephros says it had no opportunity to address the agency's questions before the decision was rendered. "We feel that the issues raised in the current letter are addressable," the company said July 7. According to the firm, the HDF system removes harmful substances from patients' blood "more effectively, and with greater capacity, than existing ESRD treatment methods." After meeting with FDA, Nephros plans to file a new 510(k) or appeal the current decision

You may also be interested in...



News In Brief

Joint Commission urges caution in imaging

Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel